MA53831A - Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques - Google Patents

Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques

Info

Publication number
MA53831A
MA53831A MA053831A MA53831A MA53831A MA 53831 A MA53831 A MA 53831A MA 053831 A MA053831 A MA 053831A MA 53831 A MA53831 A MA 53831A MA 53831 A MA53831 A MA 53831A
Authority
MA
Morocco
Prior art keywords
aggregation
reducing
methods
specific antibodies
antibodies
Prior art date
Application number
MA053831A
Other languages
English (en)
Inventor
Joon Huh
Bharadwaj Jagannathan
Daxian Shan
Michael Treuheit
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53831A publication Critical patent/MA53831A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA053831A 2018-10-01 2019-09-27 Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques MA53831A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862739542P 2018-10-01 2018-10-01

Publications (1)

Publication Number Publication Date
MA53831A true MA53831A (fr) 2022-01-05

Family

ID=70055398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053831A MA53831A (fr) 2018-10-01 2019-09-27 Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques

Country Status (14)

Country Link
US (1) US20240336685A1 (fr)
EP (1) EP3860567A4 (fr)
JP (2) JP7676304B2 (fr)
CN (1) CN112789028A (fr)
AU (1) AU2019351715C1 (fr)
BR (1) BR112021006220A2 (fr)
CA (1) CA3112655A1 (fr)
CL (1) CL2021000827A1 (fr)
EA (1) EA202190955A1 (fr)
IL (1) IL281621A (fr)
MA (1) MA53831A (fr)
MX (1) MX2021003628A (fr)
SG (1) SG11202102995PA (fr)
WO (1) WO2020072306A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018214223B2 (en) * 2017-02-02 2025-08-14 Amgen Inc. Low pH pharmaceutical composition comprising T cell engaging antibody constructs
EP4200333A1 (fr) * 2020-08-24 2023-06-28 Amgen Inc. Formulation pharmaceutique comprenant un bite, un anticorps bispécifique et de la méthionine
WO2022060901A1 (fr) * 2020-09-16 2022-03-24 Amgen Inc. Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer
WO2022060878A1 (fr) * 2020-09-16 2022-03-24 Amgen Inc. Méthodes de traitement du cancer de la prostate
CA3220933A1 (fr) * 2021-06-30 2023-01-05 Amgen Inc. Procede de reconstitution d'une formulation lyophilisee
JP2025533434A (ja) * 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
WO2026002279A1 (fr) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Peptide de masque, substrat clivable, anticorps multispécifiques et leurs utilisations
WO2026072671A1 (fr) 2024-09-24 2026-04-02 City Of Hope Procédés utilisant des virus oncolytiques exprimant le bcmat et thérapies ciblées anti-bcma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009070642A1 (fr) * 2007-11-28 2009-06-04 Medimmune, Llc Formulation de protéine
EP2249809A1 (fr) * 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Composition de protéine pulvérisée et procédés de fabrication de celle-ci
HRP20240230T1 (hr) * 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
EP2916866B1 (fr) * 2012-11-06 2018-04-04 Bayer Pharma Aktiengesellschaft Formulation d'activateurs de lymphocytes t bispécifiques (bite)
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
AR100268A1 (es) * 2014-05-07 2016-09-21 Takeda Gmbh Formulación líquida que comprende compuesto neutralizante de gm-csf
WO2016036678A1 (fr) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations d'anticorps bispécifiques
EP3226896A1 (fr) * 2014-12-02 2017-10-11 Biogen MA Inc. Procédés et compositions de lutte contre l'agrégation d'anticorps
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MX2018008300A (es) * 2016-01-13 2018-09-21 Genmab As Formulacion para anticuerpo y conjugado de farmaco del mismo.
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CA3011942A1 (fr) * 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
KR102700015B1 (ko) * 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
TWI827570B (zh) * 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程

Also Published As

Publication number Publication date
AU2019351715A1 (en) 2021-04-22
CN112789028A (zh) 2021-05-11
AU2019351715C1 (en) 2026-04-30
AU2019351715B2 (en) 2025-11-27
JP7676304B2 (ja) 2025-05-14
EA202190955A1 (ru) 2021-08-17
JP2025160922A (ja) 2025-10-23
MX2021003628A (es) 2021-05-27
WO2020072306A1 (fr) 2020-04-09
CA3112655A1 (fr) 2020-04-09
JP2022512569A (ja) 2022-02-07
BR112021006220A2 (pt) 2021-07-06
CL2021000827A1 (es) 2021-10-15
KR20210070314A (ko) 2021-06-14
US20240336685A1 (en) 2024-10-10
EP3860567A1 (fr) 2021-08-11
IL281621A (en) 2021-05-31
SG11202102995PA (en) 2021-04-29
EP3860567A4 (fr) 2022-07-06

Similar Documents

Publication Publication Date Title
EP3860567A4 (fr) Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3811971A4 (fr) Anticorps permettant de bloquer l'interaction cd47-sirpa et application associée
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3532613A4 (fr) Méthodes et compositions pour le mappage d'arn
EP3658589C0 (fr) Anticorps anti-sirp-alpha et méthodes associées
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3359573A4 (fr) Marquage d'anticorps
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3752536A4 (fr) Anticorps anti-her2
EP3399992A4 (fr) Anticorps autoréticulants
EP3452084A4 (fr) Anticorps anti-kv 1.3 et procédés pour les produire et les utiliser
IL262588A (en) Humanized anti-basigin antibodies and the use thereof
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA50654A (fr) Anticorps anti-pacap
MA49257A (fr) Anticorps anti-trkb
EP3373937A4 (fr) Conjugués anticorps anti-her22-maytansine et méthodes d'utilisation de ceux-ci
EP3841813A4 (fr) Planification synchronisée de l'agrégation de porteuses